Author Interview: Professor Roy Fleischmann – March 2022

Professor Roy Fleishmann, clinical professor of medicine at the University of Texas Southwestern Medical Center.

Author Interview: Professor Rüdiger Müller

Professor Rüdiger Müller, Rheumazentrum Ostschweiz, Switzerland

Discussing Rheumatology: Tofacitinib safety and dose-switching in RA

Prof Iain McInnes reviews two papers this month, both on tofacitinib. The first looks at CV outcomes from the STAR-RA study, the second is a post-hoc analysis of ORAL Sequel looking into tofacitinib dose switching.

ORAL Surveillance Author Interview - Roy Fleischmann

Professor Roy Fleishmann, clinical professor of medicine at the University of Texas Southwestern Medical Center.

Author Interview: Professor Kevin Winthrop (January 2022)

Professor Kevin Winthrop, Professor of Medicine at Oregon Health & Science University.

Discussing Rheumatology: HZ and ILD with tofacitinib in RA

Prof Iain McInnes reviews two papers this month, and discusses the risk of herpes zoster (HZ) events in patients with RA treated with tofacitinib, as well as interstitial lung disease, an extra-articular manifestation of RA.